逼尿肌尿道外括约肌协同失调的肉毒素A治疗

目的探讨肉毒素A(BTX-A)经尿道尿道外括约肌注射,治疗逼尿肌尿道外括约肌协同失调(DESD)的效果。方法对11例因患DESD致慢性尿潴留和尿失禁患者,行经尿道尿道外括约肌注射100UBTX-A治疗,对治疗前后的残余尿(PVR)、最大尿道压(MUP)、排尿期最大逼尿肌压(MPdet)和国际尿失禁咨询委员会尿失禁评分调查简表(ICI-Q-SF)评分进行比较。结果治疗后,MUP、MPdet和ICI-Q-SF显著降低,PVR显著减少。7~30天达最大疗效,单次注射疗效持续2~3个月,重复注射可持续更长时间。无严重不良反应发生。结论BTX-A尿道外括约肌注射治疗DESD,安全,微创,疗效确切;但需要重复注射维持疗效。     

尿动力学检查对膀胱颈硬化症逼尿肌功能评价的研究

目的：探讨如何准确评价膀胱颈硬化症逼尿肌功能。方法：对78例膀胱颈硬化症患者进行了尿动力学检查。结果：单纯性逼尿肌收缩力增高者39例，术后疗效不佳的发生率为0；逼尿肌不稳定者31例，术后疗效不佳的发生率为46%；逼尿肌收缩无力者8例，术后疗效不佳的发生率为100%。结论：应用尿动力学检查来评价膀胱颈硬化症逼尿肌功能，对合理选择病倒，指导临床治疗，提高疗效有重要的价值。     

维拉帕米灌注治疗前列腺术后膀胱痉挛性疼痛的临床疗效观察

为探讨前列腺术后膀胱痉挛性疼痛的药物治疗效果，将２６例前列腺增生行耻骨上经膀胱前列腺摘除术后频繁发作膀胱逼尿肌无抑制性收缩导致膀胱痉挛性疼痛者，按随机抽样法分为两组，第１组１５例接受维拉帕米膀胱灌注治疗，第２组１１例作为对照，不用任何可能影响下尿中功能的药物。     

Detrusor sphincter dyssynergia,detrusor instability,and urethral sphincter spasticity as the urodynamic findings in the urethral syndrome: Role of treatment with a combined anticholinergic and alpha blocking agent,bladder drill,and antibiotics

The combined effect of isopropamide 5 mg plus trifluoperazine 1 mg (a combined anticholinergic and alpha-adrenergic antagonist) (Smith, Kline and French Canada Ltd, Ontario, Canada), antibiotics, and bladder drill was retrospectively assessed on 100 consecutive women, aged 16 to 47 years, presenting with the signs and symptoms of the urethral syndrome. Assessment included history, physical examination, routine bacterial and chlamydial cultures (cervical, urethral, vaginal, and urine), cystourethroscopy, and urodynamics. Urodynamic diagnoses included detrusor sphincter dyssynergia (n=84), detrusor instability (n =8), external urethral sphincter spasticity (n=4), and sensory urgency (n=1). Three patients with positive urine cultures were excluded. Urethrotrigonitis was visualized at cystourethroscopy in all patients. Only one case of chlamydial urethritis-cervicitis was identified by culture: 82% of patients had a history of prior antibiotic therapy for lower urinary tract symptoms and 21% were being treated with antibiotics at the time of their initial assessment.Following 1 month of treatment, 44 (45%) patients were cured of all symptoms, 49 (51%) were improved, 3 (3%) were unchanged and 1 (1%) was worse. Significant changes in uroflowmetry included a reduction in postvoid residual urine volume from 49 ± 28 ml to 14 ±21 ml (P=0.029) in the unstable bladder group and a conversion from intermittent to continuous uroflow patterns in the detrusor sphincter dyssynergia group (P <0.005, ²) and overall (P <0.005, ²). A statistically significant number of patients (P <0.025, ²) converted from increased to normal tracings on repeat perianal electromyography, suggesting that the pathophysiology of the urethral syndrome is urethral spasticity related to urethral inflammation rather than actual infection.We conclude that detrusor sphincter dyssynergia, bladder instability, and urethral sphincter spasticity are the common urodynamic findings in the urethral syndrome. A combination of anticholinergic and alpha blocking agent, antibiotics, and a bladder drill markedly improved (96%) symptoms in women with the urethral syndrome.     

Efficacy and Safety of Tol Terodine in People With Neurogenic Detrusor Overactivity

Abstract

Objective: To compare tolterodine with oxybutynin and placebo in people with neuragenie detrusor overactivity.

Design: Prospective, randomized, double-blind, crossover trial plus open-label comparative stage.

Participants: Ten participants with neuragenie detrusor overactivity due to spinal cord injury or multiple sclerosis who usedintermittent catheterization.

Methods: Bladder capacity on cystometrogram, a 10-day record of catheterization volumes, number of incontinent episodes perday, and perceived dry mouth using a visual analog scale (VAS) were measured for the following: (a) a blinded comparison:tolterodine, 2 mg twice daily, vs placebo, twice daily; and (b) an unblinded comparison: oxybutynin vs tolterodine, each atself-selected doses (SSDs).

Results: Tolterodine, 2 mg twice daily, was superior to placebo in enhancing catheterization volumes (P<0.0005) and reducingincontinence (P<0.001 ), but was comparable with placebo in cystometric bladder capacity. Efficacy of tolterodine SSD wascomparable with oxybutynin SSD with regard to catheterization volumes, degree of incontinence, and cystometric bladder capacity.The side effect profile (dry mouth) was comparable between tolterodine, 2 mg twice daily, and placebo, but differed significantlywhen comparing tolterodine SSD with oxybutynin SSD (P<0.05).

Conclusion: T olterodine, when used at SSDs, is comparable with oxybutynin at SSDs in enhancing bladder volume and improvingcontinence, but with less dry mouth. T olterodine at the recommended dosage of 2 mg twice daily improves incontinence and bladdervolumes compared with placebo, and without significant dry mouth. Larger doses of tolterodine may be needed to achieve best effectin this population, but further studies are required.